Determination of β-blockers in pharmaceutical and human urine by capillary electrophoresis with electrochemiluminescence detection and studies on the pharmacokinetics.

College of Material, Chemistry and Chemical Engineering, Hangzhou Normal University, Hangzhou, China.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (Impact Factor: 2.78). 02/2011; 879(13-14):871-7. DOI: 10.1016/j.jchromb.2011.02.032
Source: PubMed

ABSTRACT A novel method for simultaneous determination of atenolol, metoprolol and esmolol was proposed by capillary electrophoresis (CE) separation and electrochemiluminescence (ECL) detection. Poly-β-cyclodextrin (Poly-β-CD) was used as an additive in the running buffer to improve the separation of three analytes. The conditions for CE separation, ECL detection and effect of Poly-β-CD were investigated in detail. The three β-blockers with very similar structures were well separated and detected under the optimum conditions. The linear ranges of the standard solution for atenolol and esmolol were 2.5-125 μmol/L with a detection limit (S/N=3) of 0.5 μmol/L, and for metoprolol was 0.5-25 μmol/L with a detection limit of 0.1 μmol/L. For three β-blockers from spiked aqueous and urine samples, the accuracy and precision including intraday and interday experiments were performed by calculating the recovery, the relative standard deviations of the ECL intensity and the migration time, respectively. The developed method was applied to the determination of metoprolol content in commercial pharmaceutical, and the analytical results are in good agreement with the nominal value with recoveries in the range of 98.7-105%. The proposed method was also applied to the monitoring of pharmacokinetics for metoprolol in human body.

  • [Show abstract] [Hide abstract]
    ABSTRACT: A new method to estimate the leucine aminopeptidase (LAP, EC activity using capillary electrophoresis coupled with electrochemiluminescence (ECL) is described. The liberated proline produced by LAP catalyzing the hydrolysis reaction of leucin-proline was used as an ECL coreagent to enhance Ru(bpy)3 (2+) ECL signals efficiently. The detection limit for proline was 2.88 × 10(-6) m (signal-to-noise ratio 3), which was equal to 9.60 × 10(-8) units of LAP being used to catalyze leucin-proline for 1 min. The Michaelis constant Km (2.07 × 10(-2) mol/L) and the maximum reaction velocity Vmax (1.06 × 10(-5) mol/L/min) of LAP for leucin-proline are reported. The reaction conditions including the concentration of metal ions, incubation temperature and pH were optimized. This method was successfully applied to detect LAP activity in plasma and the results were in good agreement with that obtained by the clinical method. Copyright © 2013 John Wiley & Sons, Ltd.
    Biomedical Chromatography 03/2013; · 1.95 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A second-order multivariate calibration method based on a combination of unfolded partial least-squares (U-PLS) with residual bilinearization (RBL) has been applied to second-order data obtained from excitation-emission fluorescence matrices for determining atenolol in human urine, even in the presence of background interactions and fluorescence inner filter effects, which are both sample dependent. Atenolol is a cardioselective beta-blocker, which is considered a doping agent in shoot practice, so that its determination in urine can be required for monitoring the drug. Loss of trilinearity due to analyte-background interactions which may vary between samples, as well as inner filter effects, precludes the use of methods like parallel factor analysis (PARAFAC) that cannot handle trilinearity deviations, and justifies the employment of U-PLS. Successful analysis required to include the background in the calibration set. Unexpected components appear in new urine samples, different from those used in calibration set, requiring the second-order advantage which is obtained from a separate procedure known as residual bilinearization (RBL). Satisfactory results were obtained for artificially spiked urines, and also for real urine samples. They were statistically compared with those obtained applying a reference method based on high-performance liquid chromatography (HPLC).
    Talanta 09/2011; 85(3):1526-34. · 3.50 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A recent clinical trial assessing human autonomic cardiovascular regulation applied pacemaker channel inhibition with ivabradine, norepinephrine transporter blockade with reboxetine, and beta-adrenoreceptor blockade with metoprolol. To verify patient adherence, we developed and validated a fast UPLC-MS/MS assay measuring all three compounds simultaneously. Deuterium-labeled drugs, d(3)-ivabradine, d(5)-reboxetine and d(7)-metoprolol, served as internal standards. Sample preparation of 200μL human plasma consisted of a single liquid-liquid extraction step by means of ethyl acetate. Chromatographic separation was performed on a 50-mm long BEH C18 column with gradient elution using a mixture of water and methanol each containing 2mM ammonium acetate over 4.5min. The mass spectrometer was operated in the positive electrospray ionization (ESI+) mode. Characteristic product ions resulting from collision-induced dissociation of unlabeled and deuterium-labeled drugs with argon were used for quantification in the selected-reaction monitoring mode. We validated the method according to the European Medicines Agency (EMA) guideline on bioanalytical method validation over the range from 1ng/mL to 500ng/mL for all three analytes. Linear responses with correlation coefficients>0.99 over that range were acquired. The LOQ value was 1ng/mL for each drug. Regulatory criteria for accuracy (80-120%) and precision (RSD<15%) were met for all drugs. The internal standard-normalized matrix factor was close to 1 for low and high analyte concentrations. We successfully measured ivabradine, reboxetine, and metoprolol concentrations in 107 human plasma samples from a clinical trial. Quality control samples processed in parallel confirmed the method's reliability in a clinical setting.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 01/2013; · 2.78 Impact Factor